Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) - Total Liabilities
Based on the latest financial reports, Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has total liabilities worth CN¥181.12 Million CNY (≈ $26.50 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) cash conversion ratio to assess how effectively this company generates cash.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Total Liabilities Trend (2019–2025)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check 301089 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Xinxiang Tuoxin Pharmaceutical Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Troy Information Technology Co Ltd
SHE:300366
|
China | CN¥1.31 Billion |
|
More Provident Funds
TA:MPP
|
Israel | ILA289.57 Million |
|
Ranpak Holdings Corp
NYSE:PACK
|
USA | $591.80 Million |
|
SuZhou ChunXing Precision Mechanical Co Ltd
SHE:002547
|
China | CN¥4.90 Billion |
|
SunOpta Inc.
NASDAQ:STKL
|
USA | $516.07 Million |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥4.22 Billion |
|
Zhongfu Information Inc
SHE:300659
|
China | CN¥557.52 Million |
|
Ichitan Group Public Company Limited
BK:ICHI-R
|
Thailand | ฿1.40 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Xinxiang Tuoxin Pharmaceutical Co.Ltd..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2025)
The table below shows the annual total liabilities of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥181.12 Million ≈ $26.50 Million |
-11.96% |
| 2024-12-31 | CN¥205.72 Million ≈ $30.10 Million |
-12.73% |
| 2023-12-31 | CN¥235.72 Million ≈ $34.49 Million |
-49.51% |
| 2022-12-31 | CN¥466.89 Million ≈ $68.32 Million |
+57.54% |
| 2021-12-31 | CN¥296.35 Million ≈ $43.37 Million |
-34.95% |
| 2020-12-31 | CN¥455.61 Million ≈ $66.67 Million |
+27.72% |
| 2019-12-31 | CN¥356.74 Million ≈ $52.20 Million |
-- |
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidin… Read more